Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies

Transplantation

Volumn 98, Issue 10, 2014, Pages 1082-1088

  Marfo, Kwaku ^a   Ajaimy, Maria ^a   Colovai, Adriana ^a   Kayler, Liise ^a   Greenstein, Stuart ^a   Lubetzky, Michelle ^a   Gupta, Anjali ^a   Kamal, Layla ^a   De Boccardo, Graciela ^a   Masiakos, Peter ^a   Kinkhabwala, Milan ^a   Akalin, Enver ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Acute rejection; Donor specific antibody; Intravenous immunoglobulin; Renal transplantation

Indexed keywords

CREATININE; HLA ANTIBODY; IMMUNOGLOBULIN; THYMOCYTE ANTIBODY; ALLOANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; B LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL PARAMETERS; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; T LYMPHOCYTE; ADVERSE EFFECTS; AGED; ANTIBODY SPECIFICITY; BLOOD; DONOR; GRAFT REJECTION; HOSPITAL ADMISSION; IMMUNOLOGY; MIDDLE AGED; MORTALITY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODY SPECIFICITY; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84926416994     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000191     Document Type: Article

References (34)

1. Ling M, Marfo K, Masiakos P, et al. Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. Hum Immunol 2012;73:879.
2. Marfo K, Lu A, Ling M, et al. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011;6:922.
3. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004;15:3256.
4. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242.
5. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010;89:1095.
6. Alachkar N, Lonze BE, Zachary AA, et al. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. Transplantation 2012;94:165.
7. Lobashevsky AL, Higgins NG, Rosner KM, et al. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation 2013;96:182.
8. Machimoto T, Guerra G, Burke G, et al. Effect of IVIG administration on complement activation and HLA antibody levels. Transpl Int 2010;23:1015.
9. Nair V, Sawinski D, Akalin E, et al. Effect of high-dose intravenous immunoglobulin on anti-HLA antibodies in sensitized kidney transplant candidates. Clin Transplant 2012;26:E261.
10. Marfo K, Ling M, Bao Y, et al. Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation 2012;94:345.
11. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21:1398.
12. Haririan A, Nogueira J, Kukuruga D, et al. Positive cross-match living donor kidney transplantation: longer-term outcomes. Am J Transplant 2009;9:536.
13. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013;13:76.
14. Gloor JM, Cosio FG, Rea DJ, et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006;6:1841.
15. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007;7:2124.
16. Rafiq MA, de Boccardo G, Schroppel B, et al. Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant 2009;23:951.
17. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complementdependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch-positive patients. Transplantation 2003;76:1444.
18. Akalin E, Ames S, Sehgal V, et al. Intravenous immunoglobulin and thymoglobulin induction treatment in immunologically high-risk kidney transplant recipients. Transplantation 2005;79:742.
19. Akalin E, Dinavahi R, Friedlander R, et al. Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodies. Clin J Am Soc Nephrol 2008;3:1160.
20. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008;8:2684.
21. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010;10:582.
22. Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008;8:324.
23. Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012;23:2061.
24. Otten HG, Verhaar MC, Borst HP, et al. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012;12:1618.
25. Patel AM, Pancoska C, Mulgaonkar S, et al. Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant 2007;7:2371.
26. Reinsmoen NL, Cornett KM, Kloehn R, et al. Pretransplant donorspecific and non-specific immune parameters associated with early acute rejection. Transplantation 2008;85:462.
27. Higgins R, Hathaway M, Lowe D, et al. Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: resolution of rejection in the presence of circulating donor-specific antibody. Transplantation 2007;84:876.
28. Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95:19.
29. Aubert V, Venetz JP, Pantaleo G, et al. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009;70:580.
30. Vlad G, Ho EK, Vasilescu ER, et al. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009;70:589.
31. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013;369:1215.
32. Akalin E, Watschinger B. Antibody-mediated rejection. Semin Nephrol 2007;27:393.
33. Kimball PM, Baker MA, Wagner MB, King A. Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Int 2011;79:1131.
34. Gombos P, Opelz G, Scherer S, et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 2013;13:2075.